Classification of Molecular Genetic Testing Technologies

Molecular genetic testing technologies serve as the indispensable core of modern medicine and life science research, operating at the DNA level to decode the complexities of human genetics. Driven by the completion of the Human Genome Project and the rapid evolution of sequencing platforms, the field has transitioned from analyzing isolated targets to capturing panoramic views of the entire genome. In both clinical diagnostics and scientific research, these technologies are systematically categorized into three distinct tiers based on their scope, resolution, and throughput: targeted molecular assays, chromosome-level analyses, and whole-genome sequencing technologies. Grasping the logic behind this classification and the specific applications of each tier is essential for accurate genetic diagnosis and effective clinical intervention.
Targeted molecular assays focus exclusively on known genes or specific variant loci. Characterized by high sensitivity, exceptional specificity, and relatively low operational costs, these methodologies remain the workhorses of routine clinical screening and variant confirmation.

• Polymerase Chain Reaction (PCR) and Derivatives: PCR stands as the foundational pillar of molecular genetics. Real-time quantitative PCR (qPCR) utilizes specific fluorescent probes to amplify and simultaneously detect target sequences, making it ideal for confirming known point mutations or microdeletions. Conversely, digital PCR (dPCR) partitions the sample into thousands of microscopic droplets to achieve absolute quantification without the need for standard curves. This makes dPCR exceptionally powerful for detecting low-frequency variants, such as circulating tumor DNA (ctDNA) in liquid biopsies.
• Sanger Sequencing (First-Generation Sequencing): Widely regarded as the "gold standard" of sequencing, Sanger sequencing determines DNA sequences via the dideoxy chain-termination method. Although it suffers from low throughput, its unparalleled accuracy and long read lengths (typically 800–1000 base pairs) ensure its continued relevance. Today, it is primarily deployed for the definitive confirmation of single-gene mutations or the sequential screening of small genomic fragments.
• Fluorescence In Situ Hybridization (FISH): FISH employs fluorescently labeled nucleic acid probes that hybridize to complementary sequences within the cell nucleus, visualized directly via fluorescence microscopy. This technique provides aintuitive spatial representation of specific gene amplifications, deletions, and positional rearrangements, establishing it as a critical tool for diagnosing microdeletion and microduplication syndromes.

Chromosome-Level Analysis Technologies

When the diagnostic focus shifts from individual genes to larger structural alterations or copy number variations (CNVs) across entire chromosomes, targeted approaches often fall short due to their limited scope. This gap is addressed by chromosome-level analytical technologies.

• Karyotyping: By employing banding techniques such as G-banding, karyotyping allows for the direct optical observation of chromosome morphology and number during metaphase. It remains the traditional, robust method for diagnosing chromosomal aneuploidies (e.g., Down syndrome) and large-scale translocations or inversions. However, its resolution is inherently limited, typically incapable of detecting variants smaller than 5–10 megabases (Mb).
• Chromosomal Microarray Analysis (CMA): Encompassing technologies such as array Comparative Genomic Hybridization (aCGH) and Single Nucleotide Polymorphism arrays (SNP-array), CMA bypasses the need for cell culture. By leveraging high-density chip hybridization, it screens the entire genome for CNVs at a resolution reaching the tens of kilobases (kb) level. CMA has consequently emerged as the first-line diagnostic test for unexplained intellectual disabilities, developmental delays, and congenital anomalies.

Whole-Genome and High-Throughput Sequencing Technologies

The advent of Next-Generation Sequencing (NGS) fundamentally revolutionized the paradigm of molecular genetic testing, shifting the diagnostic strategy from a "hypothesis-driven" approach to a powerful "data-driven" exploration.

• Targeted Panel Sequencing and Whole-Exome Sequencing (WES): These methods utilize specific probes to capture and enrich predetermined genomic regions—either a customized gene panel or the entire exome—prior to sequencing. Although the exome constitutes a mere 1–2% of the genome, it harbors approximately 85% of known disease-causing mutations. WES thus strikes an optimal balance between comprehensive diagnostic scope and economic feasibility, serving as the core technology for high-throughput screening of monogenic disorders.
• Whole-Genome Sequencing (WGS): WGS executes an unbiased sequencing of the entire genomic landscape, encompassing not only exons but also introns, regulatory elements, and intergenic regions. It possesses the unique capability to simultaneously detect single nucleotide variants (SNVs), small insertions/deletions (InDels), CNVs, and complex structural variations (SVs). As the most comprehensive and highest-resolution tool available, WGS is progressively transitioning from pure research into routine clinical application as costs continue to decline.

Cross-Technology Comparison and Clinical Selection Strategy

The various molecular genetic testing technologies do not exist in a state of mutual replacement; rather, they form a highly complementary ecosystem. In clinical practice, optimal test selection requires a comprehensive evaluation of the diagnostic objective, the suspected variant type, and economic constraints:

• Resolution and Throughput: Karyotyping offers the lowest resolution but provides a macroscopic view of chromosomal architecture. CMA bridges the gap by detecting medium-resolution CNVs, while NGS and WGS deliver the ultimate single-nucleotide resolution.
• Variant Type Adaptability: Point mutations and small InDels are best served by PCR or NGS; CNVs are the domain of CMA; and balanced translocations or complex structural variations still rely on karyotyping or advanced WGS algorithms for accurate inference.
• Application Scenario Evolution: Diagnostic pathways for genetic disorders generally adhere to a "macro to micro" and "low cost to high cost" algorithm. If the clinical phenotype strongly suggests a chromosomal anomaly, CMA is the initial test of choice. If a monogenic disorder is suspected, a targeted panel or WES is prioritized. When routine testing yields negative results yet a strong genetic etiology is suspected, WGS is deployed as the ultimate exhaustive diagnostic measure.

The systematic classification of molecular genetic testing technologies equips researchers and clinicians with a multidimensional toolkit to unravel genetic principles and dissect disease mechanisms. The foundational genomic data generated by these technologies serves as the bedrock for precise gene diagnosis and the burgeoning field of gene therapy. As multi-omics integration deepens and artificial intelligence algorithms become further entrenched, the traditional boundaries separating these testing modalities are beginning to blur. The future of molecular genetic testing is inevitably advancing toward a more rapid, cost-effective, and comprehensively unified paradigm.